Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
12/2003
12/31/2003CA2478508A1 Stable adenoviral vectors and methods for propagation thereof
12/31/2003CA2445515A1 Transcription factor modulating compounds and methods of use thereof
12/30/2003US6670466 Human endogenous retrovirus in breast cancer
12/30/2003US6670464 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
12/30/2003US6670342 Method of treating hepatitis delta virus infection
12/30/2003US6670333 Providing exogenous antiangiogenic protein to endothelial cells associated with said tissue
12/30/2003US6670332 Cytofectins comprising complex amphiphilic lipids in which a bioactive agent which is recognized by biological systems is joined to a Rosenthal Inhibitor core structure through an alkyl linking group
12/30/2003US6670188 Packaging systems for human recombinant adenovirus to be used in gene therapy
12/30/2003US6670186 RNA-loaded antigen presenting cells
12/30/2003US6670185 Compositions and methods for non-targeted activation of endogenous genes
12/30/2003US6670178 Primary or secondary cell having stably integrated into its genome: exogenous DNA that encodes a glucagon-like peptide 1 related peptide, and DNA sequences that direct expression of the exogenous DNA
12/30/2003US6670177 Infecting cells with a retrovirus in the presence of an immobilized material including a ligand which bings to the cell and a ligand which binds to the retrovirus
12/30/2003US6670176 Adeno-associated virus capable of expressing factor IX protein and cells comprising the same
12/30/2003US6670147 Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
12/30/2003US6670140 Determining whether test compound binds to receptor, selecting compound that binds, determining whether compound increases muscle mass or function in skeletal muscle atrophy model system, identifying compound that modulates mass or function
12/30/2003US6670138 Method of diagnosing ischemic stroke via UCP-2 detection
12/30/2003US6670136 Peptide for use in the treatment of inflammation defects
12/30/2003US6669960 Contacting drug-containing solution with compressed antisolvent fluid to precipitate drug-containing particles, feed solution including drug in cosolvent system including first and second organic solvents, separating particles
12/30/2003US6669946 Therapy; diagnosis; T cells recognize and interact with complexes of cell surface molecules such as human leukocyte antigens or major histocompatibility complexes
12/30/2003US6669942 Defective adenoviruses having a genome that includes a first recombinant DNA containing a therapeutic gene and a second rcombinant DNA containing an immunoprotective gene
12/30/2003US6669936 Gene therapy
12/30/2003US6669935 Transducing endothelial cells of arteries in brain, with genetic vectors including polynucleotides which code for cytolysis drugs; gene therapy; drug delivery
12/30/2003US6669934 Administering interleukins, cytokines, leukemia inhibitory factors, ciliary neurotrophic growth factors, oncostatins and derivatives to mammals to control pregnancy
12/30/2003CA2380690C Human osteoclast-derived cathepsin
12/30/2003CA2241923C Receptor-mediated gene transfer system for targeting tumor gene therapy
12/30/2003CA2132976C Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
12/25/2003US20030237105 Transgenic hybrid rodents; modulation phenotype
12/25/2003US20030237102 Method of reducing neuronal electrical activity with a potassium channel subunit
12/25/2003US20030237101 Stem cell factor; modulation of gene expression
12/25/2003US20030236396 Secretory signal sequences and uses thereof
12/25/2003US20030236394 Light activated gene transduction using long wavelength ultraviolet light for cell targeted gene delivery
12/25/2003US20030236389 Proteins, polynucleotides encoding them and methods of using the same
12/25/2003US20030236266 Anticancer agents; viricides; infection therapy
12/25/2003US20030236214 Process is described for the delivery of a therapeutic polynucleotide to a tissue suffering from or potentially suffering from ischemia
12/25/2003US20030236209 Compositions and methods for the therapy and diagnosis of lung cancer
12/25/2003US20030236208 Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides
12/25/2003US20030236207 Particulate complex for administering nucleic acid into a cell
12/25/2003US20030236204 Antisense modulation of histone deacetylase 2 expression
12/25/2003US20030236192 Method of modifying the release profile of sustained release compositions
12/25/2003US20030236184 Novel polynucleotides encoding lamprey GnRH-III
12/25/2003US20030235916 Cationic with cationic surfactant
12/25/2003US20030235912 Screening antibodies; cardiovascular disorders; gastrointestinal disorders
12/25/2003US20030235911 Hybrid nucleic acid
12/25/2003US20030235910 Antisense modulation of G protein-coupled receptor 49 expression
12/25/2003US20030235900 Anticancer agents
12/25/2003US20030235880 Genetic engineered nucleic acid
12/25/2003US20030235874 Expression vector comprising prostate specific enhancer sequences (PSES) and coding antiproliferative/antitumor agent for treatment of androgen-independent and androgen-dependent prostate carcinomas
12/25/2003US20030235845 Directing splicing of messenger RNA associated with dystrophin protein for diagnosis and treatment of muscular dystrophy
12/25/2003US20030235821 Novel Human proteins, polynucleotides encoding them and methods of using the same
12/25/2003US20030235592 Moraxella catarrhalis protein, gene sequence and uses thereof
12/25/2003US20030235580 Reconstituted and recombinant tissue membranes and methods for pharmaceutical delivery of bioactive molecules
12/25/2003US20030235577 Administration of MMPAP-12 polypeptides and nucleic acids
12/25/2003US20030235564 Compositions and devices comprising or encoding the Run x2 protein and method of use
12/25/2003US20030235563 Placental derived stem cells and uses thereof
12/25/2003US20030235562 Introducing a nucleic acid sequence encoding a lifespan extending or immortalizing protein product, under conditions such that it is expressed and a protein product is produced and engineering into a vascular graft
12/25/2003US20030235561 Vascularized organized tissues and uses thereof
12/25/2003US20030235557 Administering two viral vectors containing an immunogenic portion of a wilms' tumor (wt1) polynucleotide operably linked to an expression control sequence
12/25/2003US20030235536 Administering an aerosol, a conjugate of a therapeutic agent and an FcRn binding partner, for treating resipiratory system disorders, drug delivery of an antibody, immunizing vaccines
12/25/2003US20030235535 Administering a Prokineticin 2 receptor antagonist or agonist; control internal body clock and functions
12/24/2003WO2003106712A1 Antisense modulation of ptpn12 expression
12/24/2003WO2003106673A1 Method of slective isolation or visualization of target cells differentiated from embryonic stem cells or kit for visualization
12/24/2003WO2003106664A1 Process for preparing an adenovirus-containing preparation
12/24/2003WO2003106657A2 Wise/sost nucleic acid sequences and amino acid sequences
12/24/2003WO2003106647A2 Antisense modulation of junctional adhesion molecule 3 expression
12/24/2003WO2003106643A2 Novel polynucleotides encoding lamprey gnrh-iii
12/24/2003WO2003106636A2 Novel methods for the delivery of polynucleotides to cells
12/24/2003WO2003106631A2 Methods and compositions relating to labeled rna molecules that reduce gene expression
12/24/2003WO2003106630A2 Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
12/24/2003WO2003106619A2 Multifunctional polypeptides
12/24/2003WO2003106496A1 Antibodies, peptides and vaccines against hiv-1 virus
12/24/2003WO2003106476A1 Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
12/24/2003WO2003105879A1 Compositions and methods for preventing, treating and diagnosing diabetes
12/24/2003WO2003105778A2 Phosphatidylinositol-4-phosphate 5-kinase, type ii beta inhibitors for inhibiting angiogenesis
12/24/2003WO2003105761A2 Immunotoxin as a therapeutic agent and uses thereof
12/24/2003WO2003105755A2 Antisense modulation of vegf-c expression
12/24/2003WO2003105753A2 Methods and compositions for grafting functional loops into a protein
12/24/2003WO2003087294A3 Recombining viral vectors for the tetracycline-regulated expression of genes
12/24/2003WO2003083113A3 Growth regulating proteins
12/24/2003WO2003083080A3 Mixed- cell gene therapy
12/24/2003WO2003079020A3 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
12/24/2003WO2003075951A3 Novel application of vaccination against tnf-alpha
12/24/2003WO2003072741A3 Therapeutic regulation of deoxyribonuclease-1-like-3 activity
12/24/2003WO2003070914A3 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/24/2003WO2003070283A3 Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
12/24/2003WO2003068925A3 Production of a protein delivery system for in vivo therapeutic treatment
12/24/2003WO2003066840A3 Pluripotent embryonic-like stem cells derived from teeth and uses thereof
12/24/2003WO2003064473A3 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
12/24/2003WO2003050251A3 Hematopoietic cells from human embryonic stem cells
12/24/2003WO2003047611A3 Ptp10d, tec and edtp involved in triglycerid-metabolism
12/24/2003WO2003040294A3 METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs
12/24/2003WO2003037920A3 Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration
12/24/2003WO2003037362A3 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
12/24/2003WO2002102997A3 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
12/24/2003WO2002102990A8 Fibroblast growth factor and nucleic acid encoding same
12/24/2003WO2002102825A3 Fluorescently labelled locked nucleic acids
12/24/2003WO2002094177A3 Novel nucleic acids and their therapeutic use in ophthalmology
12/24/2003WO2002081703A3 Mitogenic oxygenase regulators
12/24/2003WO2002068669A3 Matrix attachment regions containing episomal vectors for use in cell-specific gene expression
12/24/2003WO2002066601A3 Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam2
12/24/2003WO2001092542A8 Integrin-targeting vectors having enhanced transfection activity
1 ... 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 ... 870